

# Bettina E Hansen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1326109/bettina-e-hansen-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152  
papers

11,309  
citations

54  
h-index

104  
g-index

158  
ext. papers

12,925  
ext. citations

6.6  
avg, IF

5.65  
L-index

#	Paper	IF	Citations
152	Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. <i>European Radiology</i> , <b>2022</b> , 32, 67-77	8	1
151	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1451-1458.e4	6.9	3
150	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1688-1697.e14	6.9	5
149	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1933-1940.e1	6.9	2
148	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 498-510	35.1	89
147	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1546-1557	15.4	14
146	Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 689-698	6.1	0
145	Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 463-472	6.9	15
144	Identification of prosthetic hip and knee joint infections using administrative databases-A validation study. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 42, 325-330	2	4
143	Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2021</b> , 41, 535-544	7.9	3
142	Psychological consequences of MRI-based screening among women with strong family histories of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 497-508	4.4	0
141	Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. <i>Transplant International</i> , <b>2021</b> , 34, 1444-1454	3	1
140	The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single-Center Analysis. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1733-1746	4.5	1
139	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. <i>Liver Transplantation</i> , <b>2020</b> , 26, 799-810	4.5	8
138	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 649-657	18.8	38
137	Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1509-1517.e7	6.9	11
136	Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 905-913	35.1	33

135	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , <b>2020</b> , 104, 2087-2096	1.8	7
134	Pediatric Wilson Disease Presenting as Acute Liver Failure: An Individual Patient Data Meta-analysis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2020</b> , 71, e90-e96	2.8	3
133	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 259-261	6.9	1
132	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 684-692.e6	6.9	10
131	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2076-2084.e2	6.9	27
130	Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 992-999	13.4	9
129	Predictors of Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of 1- and 2-Stage Exchange Arthroplasty: A Multicenter Retrospective Cohort. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz452	1	23
128	Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 666-673	13.4	35
127	Is Textbook Outcome a valuable composite measure for short-term outcomes of gastrointestinal treatments in the Netherlands using hospital information system data?. <i>BMJ Open</i> , <b>2018</b> , 8, e019405	3	21
126	Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1098-1105.e1	6.9	23
125	Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. <i>Gastroenterology</i> , <b>2018</b> , 154, 515-517.e3	13.3	71
124	Risk stratification and prognostic modelling in primary biliary cholangitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 34-35, 95-106	2.5	5
123	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. <i>Gastroenterology</i> , <b>2018</b> , 155, 1392-1399.e5	13.3	13
122	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8	13.3	219
121	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , <b>2015</b> , 64, 1289-95	19.2	146
120	Use of visible light spectroscopy to diagnose chronic gastrointestinal ischemia and predict response to treatment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 122-30.e1	6.9	15
119	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , <b>2015</b> , 64, 322-31	19.2	28
118	High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 87-8	3.3	1

117	Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). <i>Gut</i> , <b>2014</b> , 63, 292-9	19.2	162
116	Immunoglobulin G4-related prostatitis: a case-control study focusing on clinical and pathologic characteristics. <i>Urology</i> , <b>2014</b> , 83, 521-6	1.6	31
115	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 482-91	13.4	18
114	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 191-6	13.4	30
113	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. <i>Gastroenterology</i> , <b>2014</b> , 147, 1338-49.e5; quiz e15	13.3	265
112	Serum liver enzymes are associated with all-cause mortality in an elderly population. <i>Liver International</i> , <b>2014</b> , 34, 296-304	7.9	59
111	Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. <i>Pancreas</i> , <b>2014</b> , 43, 261-7	2.6	25
110	Drug therapies for ulcerative proctitis: systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 2157-78	4.5	13
109	Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 427-35	1.9	7
108	A comparative study of diagnostic scoring systems for autoimmune pancreatitis. <i>Pancreas</i> , <b>2014</b> , 43, 559-64	2.6	12
107	Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. <i>Vaccine</i> , <b>2013</b> , 31, 1040-4	4.1	37
106	Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 898-903	13.4	40
105	MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1231-8	13.4	44
104	Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , <b>2013</b> , 97, 312-7	10.8	15
103	External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 1201-4	6.9	128
102	Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 100-5	11.6	28
101	Sustained virological response to treatment in patients with chronic hepatitis C--reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1457	27.4	3
100	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , <b>2013</b> , 62, 760-5	19.2	132

99	Histological features in western patients with idiopathic non-cirrhotic portal hypertension. <i>Histopathology</i> , <b>2013</b> , 62, 1083-91	7.3	56
98	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , <b>2013</b> , 58, 872-80	11.2	163
97	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 11	3	26
96	Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 1305-11	13.4	144
95	Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfecting with HBV and HIV. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 974-80	7	57
94	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. <i>Liver International</i> , <b>2012</b> , 32, 622-8	7.9	58
93	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1006-1011	13.4	133
92	Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. <i>Gastroenterology</i> , <b>2012</b> , 142, 513-520.e1	13.3	134
91	Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , <b>2012</b> , 36, 641-7	5.6	58
90	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , <b>2012</b> , 56, 67-75	11.2	64
89	Continuous interferon- $\alpha$ b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 509-17	1.6	3
88	Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon- $\alpha$ b: relation to response and HBV genotype. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 9-17	1.6	54
87	Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 657-67	1.6	24
86	NcoI TNF- $\beta$ gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 378-86	2.4	16
85	Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. <i>Journal of Human Genetics</i> , <b>2012</b> , 57, 26-32	4.3	23
84	Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2584-93	27.4	1089
83	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon $\alpha$ 2a: progressive decrease in hepatitis B surface antigen in responders. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 1012-9	2.2	10
82	Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1605-8	1.6	13

81	Endoscopic visible light spectroscopy: a new, minimally invasive technique to diagnose chronic GI ischemia. <i>Gastrointestinal Endoscopy</i> , <b>2011</b> , 73, 291-8	5.2	47
80	A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , <b>2011</b> , 51, 175-8	14.5	45
79	Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 449-54	13.4	117
78	Serum markers and intestinal mucosal injury in chronic gastrointestinal ischemia. <i>Digestive Diseases and Sciences</i> , <b>2011</b> , 56, 506-12	4	22
77	HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 1917-23	19.7	2
76	Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , <b>2011</b> , 54, 443-51	11.2	132
75	Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 962-72	2.4	43
74	Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 415-8	7	107
73	A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 984-91	7	30
72	A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1762-9	0.7	71
71	Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. <i>Gastroenterology</i> , <b>2010</b> , 139, 491-8	13.3	156
70	Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. <i>Gastroenterology</i> , <b>2010</b> , 139, 1934-41	13.3	104
69	Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 493-500	13.4	96
68	Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 468-76	13.4	64
67	Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 455-9	13.4	36
66	Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 1495-502	2.2	33
65	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. <i>Hepatology</i> , <b>2010</b> , 52, 454-61	11.2	188
64	The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , <b>2010</b> , 52, 1334-40	11.2	71

63	Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Hepatology</i> , <b>2010</b> , 52, 1225-31	11.2	45
62	Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. <i>Hepatology</i> , <b>2010</b> , 52, 1251-7	11.2	225
61	Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1135-42	19.7	37
60	Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. <i>Liver Transplantation</i> , <b>2010</b> , 16, 837-46	4.5	55
59	Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. <i>BMC Gastroenterology</i> , <b>2010</b> , 10, 144	3	27
58	Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution. <i>Statistics in Medicine</i> , <b>2010</b> , 29, 3267-83	2.3	15
57	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 1443-8	2.2	1
56	Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2449-57	10.7	21
55	A randomized comparison of electrocautery incision with Savary bougienage for relief of anastomotic gastroesophageal strictures. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 70, 849-55	5.2	93
54	Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. <i>Journal of Vascular Surgery</i> , <b>2009</b> , 50, 687-9	3.5	27
53	Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. <i>Gastroenterology</i> , <b>2009</b> , 136, 1281-7	13.3	311
52	Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. <i>Gastroenterology</i> , <b>2009</b> , 137, 2002-9	13.3	300
51	Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. <i>Liver International</i> , <b>2008</b> , 28, 249-56	7.9	38
50	Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. <i>Gastroenterology</i> , <b>2008</b> , 135, 459-67	13.3	301
49	Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. <i>Gastrointestinal Endoscopy</i> , <b>2008</b> , 67, 821-7	5.2	41
48	A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 292-4	7	54
47	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. <i>Hepatology</i> , <b>2008</b> , 47, 1856-62	11.2	226
46	Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6. <i>Hepatology</i> , <b>2007</b> , 45, 258-9	11.2	6

45	Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. <i>Hepatology</i> , <b>2007</b> , 46, 388-94	11.2	87
44	Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 1055-63	19.7	37
43	Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. <i>Liver International</i> , <b>2007</b> , 27, 1217-25	7.9	28
42	Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey. <i>Quality of Life Research</i> , <b>2007</b> , 16, 375-88	3.7	32
41	Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. <i>Hepatology</i> , <b>2006</b> , 44, 721-7	11.2	57
40	Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2044-50	0.7	128
39	Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 297-303	0.7	203
38	Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2523-9	0.7	23
37	Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. <i>Scandinavian Journal of Gastroenterology</i> , <b>2006</b> , 41, 1087-94	2.4	30
36	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 539-46	13.4	66
35	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. <i>Lancet, The</i> , <b>2005</b> , 365, 123-9	40	948
34	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 250-7	13.4	127
33	Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2005</b> , 17, 1173-9	2.2	26
32	Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients. <i>Clinical Transplantation</i> , <b>2005</b> , 19, 537-42	3.8	4
31	Heterotopic vs. orthotopic liver transplantation for chronic liver disease: a case-control comparison of short-term and long-term outcomes. <i>Liver Transplantation</i> , <b>2005</b> , 11, 396-401	4.5	12
30	Integrity of the anal sphincters after pouch-anal anastomosis: evaluation with three-dimensional endoanal ultrasonography. <i>Diseases of the Colon and Rectum</i> , <b>2005</b> , 48, 1728-35	3.1	15
29	Volume measurements of the anal sphincter complex in healthy controls and fecal-incontinent patients with a three-dimensional reconstruction of endoanal ultrasonography images. <i>Diseases of the Colon and Rectum</i> , <b>2005</b> , 48, 540-8	3.1	49
28	The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. <i>Quality of Life Research</i> , <b>2004</b> , 13, 1469-81	3.7	39



27	Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. <i>BMC Gastroenterology</i> , <b>2004</b> , 4, 13	3	42
26	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. <i>Hepatology</i> , <b>2004</b> , 39, 500-8	11.2	267
25	Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. <i>Hepatology</i> , <b>2004</b> , 39, 804-10	11.2	287
24	Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 689-95	13.4	34
23	Prior radiation and/or chemotherapy has no effect on the outcome of metal stent placement for oesophagogastric carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 163-70	2.2	85
22	Metastases in supraclavicular lymph nodes in lung cancer: assessment with palpation, US, and CT. <i>Radiology</i> , <b>2004</b> , 232, 75-80	20.5	70
21	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. <i>Journal of Virological Methods</i> , <b>2003</b> , 110, 201-9	2.6	152
20	Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. <i>BMC Gastroenterology</i> , <b>2003</b> , 3, 24	3	15
19	Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. <i>BMC Gastroenterology</i> , <b>2003</b> , 3, 33	3	53
18	Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 1528-32	7	15
17	Viral dynamics in chronic hepatitis B patients during lamivudine therapy. <i>Liver</i> , <b>2002</b> , 22, 121-6		31
16	Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 1007-11	2.2	23
15	The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. <i>Journal of Hepatology</i> , <b>2002</b> , 37, 253-8	13.4	30
14	Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2002</b> , 37, 137-44	13.4	61
13	Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. <i>Journal of Hepatology</i> , <b>2001</b> , 34, 435-40	13.4	31
12	US and fluoroscopic-guided percutaneous jejunostomy: experience in 49 patients. <i>Journal of Vascular and Interventional Radiology</i> , <b>2000</b> , 11, 101-6	2.4	44
11	Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. <i>Gastroenterology</i> , <b>1999</b> , 117, 408-13	13.3	128
10	Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 192-8	13.4	75

9	Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 256-62	13.4	39
8	Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. <i>Journal of Hepatology</i> , <b>1998</b> , 28, 951-9	13.4	38
7	Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. <i>Journal of Hepatology</i> , <b>1997</b> , 26, 961-6	13.4	193
6	The cervical spine in rheumatoid arthritis: relationship between neurologic signs and morphology of MR imaging and radiographs. <i>Skeletal Radiology</i> , <b>1996</b> , 25, 113-8	2.7	35
5	Quantification of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. <i>American Heart Journal</i> , <b>1995</b> , 130, 828-37	4.9	153
4	Comparison of echocardiographic methods with magnetic resonance imaging for assessment of right ventricular function in children. <i>American Journal of Cardiology</i> , <b>1995</b> , 76, 589-94	3	225
3	Effect of blood group and HLA matching on pancreas graft survival with the use of UW solution. <i>Transplant International</i> , <b>1995</b> , 8, 366-73	3	1
2	Reproducible radiographs of acetabular prostheses. A method assessed in 35 patients. <i>Acta Orthopaedica</i> , <b>1994</b> , 65, 258-62		5
1	Neuroenteric peptides affect natural killer activity by intestinal lamina propria mononuclear cells. <i>Journal of Neuroimmunology</i> , <b>1993</b> , 42, 139-45	3.5	18